Literature DB >> 22824638

Brown-Vialetto-van Laere and Fazio-Londe overlap syndromes: a clinical, biochemical and genetic study.

Marianna Ciccolella1, Michela Catteruccia, Sabina Benedetti, Isabella Moroni, Graziella Uziel, Chiara Pantaleoni, Luisa Chiapparini, Alberto Bizzi, Adele D'Amico, Fabiana Fattori, Maria Letizia Salsano, Anna Pastore, Giulia Tozzi, Fiorella Piemonte, Enrico Bertini.   

Abstract

Brown-Vialetto-van Laere (BVVL) and Fazio-Londe (FL) are rare and clinically overlapping motor neurons syndromes. Recently BVVL has been associated with mutations in C20orf54/hRFT2 and defective riboflavin transport. We compared clinical and laboratory features of 6 patients (age range 11-17 years), with features of BVVL and FL overlap syndromes. Patients were assessed as following: blood levels of riboflavin and redox status, electrophysiological, neuroradiological and pulmonary studies, ALS functional rating scale and molecular genetic analysis. Two patients manifested deafness at ages of 3 and 10 years, and developed later subacute progressive ponto-bulbar palsy. A third patient markedly improved after intravenous immunoglobulins (IVIG), but then relapsed remaining unresponsive to treatment; he was not deaf although had abnormal auditory evoked responses (BAERs). The remaining 3 patients had no deafness, although likewise manifested subacute progressive ponto-bulbar palsy. We found hRFT2 mutations in 3/6 patients manifesting deafness or abnormal BAERs. No patient had reduced riboflavin blood levels. However, on riboflavin supplementation (10mg/kg/day) the most severely affected BVVL patient stopped progression of symptoms following 8 months of treatment. BVVL and FL are severe progressive diseases with overlapping symptoms although only hRFT2 mutated patients manifest deafness. Riboflavin supplementation seems to stabilize and improve progression of the disease.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22824638     DOI: 10.1016/j.nmd.2012.05.007

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  10 in total

1.  EGR2 mutation enhances phenotype spectrum of Dejerine-Sottas syndrome.

Authors:  Elena Gargaun; Andreea Mihaela Seferian; Ruxandra Cardas; Anne-Gaelle Le Moing; Catherine Delanoe; Juliette Nectoux; Isabelle Nelson; Gisèle Bonne; Marie-Thérèse Bihoreau; Jean-François Deleuze; Anne Boland; Cécile Masson; Laurent Servais; Teresa Gidaro
Journal:  J Neurol       Date:  2016-05-09       Impact factor: 4.849

2.  Fazio Londe syndrome: A treatable disorder.

Authors:  Poovazhagi Varadarajan; Vimal Thayanathi; Leema C Pauline
Journal:  Ann Indian Acad Neurol       Date:  2015 Jan-Mar       Impact factor: 1.383

3.  Treatable childhood neuronopathy caused by mutations in riboflavin transporter RFVT2.

Authors:  A Reghan Foley; Manoj P Menezes; Amelie Pandraud; Michael A Gonzalez; Ahmad Al-Odaib; Alexander J Abrams; Kumiko Sugano; Atsushi Yonezawa; Adnan Y Manzur; Joshua Burns; Imelda Hughes; B Gary McCullagh; Heinz Jungbluth; Ming J Lim; Jean-Pierre Lin; Andre Megarbane; J Andoni Urtizberea; Ayaz H Shah; Jayne Antony; Richard Webster; Alexander Broomfield; Joanne Ng; Ann A Mathew; James J O'Byrne; Eva Forman; Mariacristina Scoto; Manish Prasad; Katherine O'Brien; Simon Olpin; Marcus Oppenheim; Iain Hargreaves; John M Land; Min X Wang; Kevin Carpenter; Rita Horvath; Volker Straub; Monkol Lek; Wendy Gold; Michael O Farrell; Sebastian Brandner; Rahul Phadke; Kazuo Matsubara; Michael L McGarvey; Steven S Scherer; Peter S Baxter; Mary D King; Peter Clayton; Shamima Rahman; Mary M Reilly; Robert A Ouvrier; John Christodoulou; Stephan Züchner; Francesco Muntoni; Henry Houlden
Journal:  Brain       Date:  2013-11-19       Impact factor: 13.501

4.  Disruption of Slc52a3 gene causes neonatal lethality with riboflavin deficiency in mice.

Authors:  Hiroki Yoshimatsu; Atsushi Yonezawa; Kaori Yamanishi; Yoshiaki Yao; Kumiko Sugano; Shunsaku Nakagawa; Satoshi Imai; Tomohiro Omura; Takayuki Nakagawa; Ikuko Yano; Satohiro Masuda; Ken-Ichi Inui; Kazuo Matsubara
Journal:  Sci Rep       Date:  2016-06-08       Impact factor: 4.379

5.  Genome-wide RNA-seq of iPSC-derived motor neurons indicates selective cytoskeletal perturbation in Brown-Vialetto disease that is partially rescued by riboflavin.

Authors:  Federica Rizzo; Agnese Ramirez; Claudia Compagnucci; Sabrina Salani; Valentina Melzi; Andreina Bordoni; Francesco Fortunato; Alessia Niceforo; Nereo Bresolin; Giacomo P Comi; Enrico Bertini; Monica Nizzardo; Stefania Corti
Journal:  Sci Rep       Date:  2017-04-06       Impact factor: 4.379

6.  A juvenile ALS-like phenotype dramatically improved after high-dose riboflavin treatment.

Authors:  Christophe Carreau; Timothée Lenglet; Isabelle Mosnier; Ghizlene Lahlou; Guillaume Fargeot; Nicolas Weiss; Sophie Demeret; François Salachas; Alice Veauville-Merllié; Cécile Acquaviva; Yann Nadjar
Journal:  Ann Clin Transl Neurol       Date:  2020-02-05       Impact factor: 4.511

Review 7.  The Brown-Vialetto-Van Laere and Fazio Londe syndrome revisited: natural history, genetics, treatment and future perspectives.

Authors:  Annet M Bosch; Kevin Stroek; Nico G Abeling; Hans R Waterham; Lodewijk Ijlst; Ronald J A Wanders
Journal:  Orphanet J Rare Dis       Date:  2012-10-29       Impact factor: 4.123

Review 8.  Clinical and genetic diversity of SMN1-negative proximal spinal muscular atrophies.

Authors:  Kristien Peeters; Teodora Chamova; Albena Jordanova
Journal:  Brain       Date:  2014-06-25       Impact factor: 13.501

Review 9.  Clinical presentation and outcome of riboflavin transporter deficiency: mini review after five years of experience.

Authors:  Bregje Jaeger; Annet M Bosch
Journal:  J Inherit Metab Dis       Date:  2016-03-14       Impact factor: 4.982

10.  A Case of Brown-Vialetto-Van Laere Syndrome Due To a Novel Mutation in SLC52A3 Gene: Clinical Course and Response to Riboflavin.

Authors:  Venkatraman Thulasi; Aravindhan Veerapandiyan; Beth A Pletcher; Chun M Tong; Xue Ming
Journal:  Child Neurol Open       Date:  2017-08-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.